With great power comes great responsibility. As ESG momentum intensifies, the scrutiny over the pharmaceutical sector’s role in society is increasing. How 'pharma' evolves to meet fresh ESG challenges will present challenges and opportunities for the sector's constituents.
Undoubtedly, the Glaxos, Astras and Sanofis of the world have a significant role to play in the health of society. However, improving access to healthcare, creating therapies and vaccines, and driving medicine affordability, while keeping stakeholders happy, is not an easy remit. When considering ESG, it is important to stress an obvious statement: every sector is different, facing different sets of challenges and opportunities to varying degrees, and so the definition and materiality of ESG factors will also differ accordingly. Asset management industry must 'do more' to tackle racia...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
